Bleeding Disorders FVIII Research, excluding inhibitors research

Proposals should involve laboratory scientist/clinician collaboration and may be multi-institutional. Designed to facilitate an eventual clinical trial. If at that time the project is ready for clinical trial, further funding may be available to support that trial.

ELIGIBILITY: Applicants must hold an M.D., Ph.D. or equivalent degree and should be working for a domestic or foreign non profit institution or organization. Applicants need not be U.S. citizens and there are no restrictions on applicant age, race, gender or creed.

AWARDS: Awards of up to $100,000 for total direct costs to be funded over a two-year grant term will be available initially. Institutional costs cannot exceed 10% each year鈥檚 budget. The funding period for selected projects shall be July 1, 2013 through June 30, 2014.

DEADLINE: A Letter of Intent with a description of the proposed research plan, proposed methods and preliminary data should be submitted by May 1, 2013, with the CVs and bibliographies of the investigators. The letter of intent must not exceed 2 single-spaced pages (in 12 pt. Times New Roman font).

After initial review, a number of applicants will be invited to submit full applications. Review of the full applications will be completed by July 2013.

SUBMISSION: Mail: Email:

Medical & Scientific Committee

Hemophilia Association of New York &

131 West 33rd Street, Suite 11D

New York, NY 10001

The Hemophilia Association of New York is an independent voluntary health organization.

Telephone: 212-682-5510 / Fax: 212-983-1114 / Email:


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.